In a recently accepted manuscript titled “Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data”, scientists from Insilico Medicine, Inc located at the Emerging Technology Centers at Johns Hopkins University in collaboration with Datalytic Solutions and Mind Research Network presented a novel approach applying deep neural networks (DNNs) to predict pharmacologic properties of many drugs.
In this special guest feature, Rani Hublou, Chief Product Officer at Comprehend, provides her views on why pharmaceutical data is such a sticking point for the R&D process.
Arterys Inc., a privately-held company dedicated to deep learning medical imaging technology, continues to advance improved imaging capabilities bringing artificial intelligence called deep learning to the healthcare field, beginning with the heart.
You can now access the genome sequence data of 3,024 rice varieties that have been aligned and analyzed against five different reference genomes as an AWS Public Data Set. The data contains over 30 million genetic variations that span across all known and predicted rice genes, as well as potential regulatory regions surrounding these genes.
Sinequa, a leader in real-time Big Data search and analytics, today announced that UCB has selected the Sinequa Big Data Search & Analytics Platform to speed vital information discovery of its clinical trial file share.
Qubole, the big data-as-a-service company, announced that Station X, a leading developer of technologies that make large-scale human genome management and analysis easier, is using Presto on Qubole’s cloud-based big data platform to power GenePool™, a powerful software-as-a-service solution for real-time analytics of genomic and medical information.
This executive report is based on an in-depth study by the IBM Institute for Business Value research team. It looks at the current state of analytics across the healthcare ecosystem, including how organizations are implementing analytics strategies.
In the presentation below, Dr. Geoffrey E. Hinton, Distinguished Researcher at Google, discusses how recent advances in machine learning cast new light on two puzzling biological phenomena.
Insilico Medicine to Utilize Deep Learning for Drug Repurposing and Discovery in Cancer and Age-Related Disease
Insilico Medicine, a bioinformatics company dedicated to drug discovery for cancer and aging, has launched its proprietary DeepPharma (TM) platform. DeepPharma utilizes the latest advances in deep learning to improve computer analysis of massive structured multi-omics data banks and millions of tissue-specific pathway activation profiles.
A new research institute at UCLA may eventually provide doctors with tools to more accurately tailor medicines for individual patients, which could both improve quality of care and minimize the side effects associated with today’s medicine.